Calidi Biotherapeutics (CLDI) EBT (2022 - 2026)

Calidi Biotherapeutics has reported EBT for 5 years, with the latest figure at -$4.2 million in Q2 2026.

• On a quarterly basis, EBT rose 27.83% year-over-year to -$4.2 million in Q2 2026; TTM through Jun 2026 was -$19.1 million, a 4.43% increase from a year earlier, with the FY2025 full-year figure at -$20.0 million, up 9.67% from the prior year.
• EBT was -$4.2 million for Q2 2026 at Calidi Biotherapeutics, down from -$4.1 million in the prior quarter.
• The five-year high for EBT was $4.2 million in Q2 2022, with the low at -$12.5 million in Q2 2023.
• Average EBT over 5 years is -$4.9 million, with a median of -$5.2 million recorded in 2025.
• The largest YoY upside for EBT was 62.4% in 2023 against a maximum downside of 541.67% in 2023.
• Over 5 years, EBT stood at -$7.8 million in 2022, then declined by 6.1% to -$8.2 million in 2023, then surged by 49.65% to -$4.1 million in 2024, then increased by 2.03% to -$4.1 million in 2025, then decreased by 2.31% to -$4.2 million in 2026.
• The last three EBT figures came in at -$4.2 million (Q2 2026), -$4.1 million (Q4 2025), and -$5.2 million (Q3 2025), per Business Quant data.